Impact of delivery time factor on treatment time and plan quality in tomotherapy.

Male Humans Radiotherapy, Intensity-Modulated Time Factors Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted Lung Neoplasms / radiotherapy

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 07 2023
Historique:
received: 23 03 2023
accepted: 19 07 2023
medline: 31 7 2023
pubmed: 28 7 2023
entrez: 27 7 2023
Statut: epublish

Résumé

Delivery time factor (DTF) is a new parameter introduced by the RayStation treatment planning system for tomotherapy treatment planning. This study investigated the effects of this factor on various tomotherapy plans. Twenty-five patients with cancer (head and neck, 6; lung, 9; prostate, 10) were enrolled in this study. Helical tomotherapy plans with a field width of 2.5 cm, pitch of 0.287, and DTF of 2.0 were created. All the initial plans were recalculated by changing the DTF parameter from 1.0 to 3.0 in increments of 0.1. Then, DTF's impact on delivery efficiency and plan quality was evaluated. Treatment time and modulation factor increased monotonically with increasing DTF. Increasing the DTF by 0.1 increased the treatment time and modulation factor by almost 10%. This relationship was similar for all treatment sites. Conformity index (CI), homogeneity index, and organ at risk doses were improved compared to plans with a DTF of 1.0, except for the CI in the lung cancer case. However, the improvement in most indices ceased at a certain DTF; nevertheless, treatment time continued to increase following an increase in DTF. DTF is a critical parameter for improving the quality of tomotherapy plans.

Identifiants

DOI: 10.1038/s41598-023-39047-z PMID: 37500671 PMC: PMC10374581
pubmed: 37500671
doi: 10.1038/s41598-023-39047-z
pii: 10.1038/s41598-023-39047-z
pmc: PMC10374581
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12207

Informations de copyright

© 2023. The Author(s).

Références

Cancers (Basel). 2019 May 13;11(5):
pubmed: 31086093
Radiat Oncol. 2015 Sep 17;10:191
pubmed: 26377574
Radiat Oncol. 2020 Nov 2;15(1):253
pubmed: 33138837
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211045497
pubmed: 34632876
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1243-51
pubmed: 19251096
Sci Rep. 2022 Feb 25;12(1):3221
pubmed: 35217707
Strahlenther Onkol. 2020 Feb;196(2):142-150
pubmed: 31300831
Radiat Oncol. 2017 Aug 10;12(1):125
pubmed: 28793907
Br J Radiol. 2016;89(1060):20150970
pubmed: 26828971
Radiat Oncol. 2022 May 7;17(1):86
pubmed: 35526019
Radiat Oncol. 2015 Dec 23;10:261
pubmed: 26701749
Med Phys. 2023 Mar;50(3):e25-e52
pubmed: 36512742
J Appl Clin Med Phys. 2023 Jan;24(1):e13781
pubmed: 36523156
Radiat Oncol. 2019 Jun 24;14(1):112
pubmed: 31234868
J Appl Clin Med Phys. 2022 Jun;23(6):e13648
pubmed: 35570390
J Appl Clin Med Phys. 2015 Sep 08;16(5):87–105
pubmed: 26699293
Br J Radiol. 2020 Apr;93(1108):20190792
pubmed: 31939310
Med Phys. 2018 Jan;45(1):18-28
pubmed: 29106739
Clin Oncol (R Coll Radiol). 2012 Apr;24(3):208-15
pubmed: 22196796
Front Oncol. 2021 Nov 05;11:764946
pubmed: 34804969
Strahlenther Onkol. 2016 Apr;192(4):232-9
pubmed: 26852243
Sci Rep. 2020 Mar 18;10(1):4928
pubmed: 32188899
Med Phys. 2020 Jul;47(7):2805-2813
pubmed: 32266979
Med Phys. 2010 Sep;37(9):4817-53
pubmed: 20964201
J Neurosurg. 2006 Dec;105 Suppl:194-201
pubmed: 18503356
Radiat Oncol. 2020 Nov 7;15(1):257
pubmed: 33160374
Med Dosim. 2015 Winter;40(4):285-9
pubmed: 25869936
J Appl Clin Med Phys. 2020 Jul;21(7):107-118
pubmed: 32363800
Radiother Oncol. 2017 Feb;122(2):295-299
pubmed: 27914680
Radiat Oncol. 2010 May 23;5:40
pubmed: 20492727
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1589-600
pubmed: 21167651
Phys Med. 2013 May;29(3):273-85
pubmed: 22521735
Strahlenther Onkol. 2021 Aug;197(8):722-729
pubmed: 33852037
J Radiat Res. 2018 Sep 1;59(5):664-668
pubmed: 29868727
Front Oncol. 2022 Mar 10;12:785917
pubmed: 35359412
J Radiat Res. 2015 Nov;56(6):889-96
pubmed: 26320208
Phys Med. 2019 Jul;63:19-24
pubmed: 31221404
Radiat Oncol. 2015 Apr 17;10:91
pubmed: 25896675
Med Phys. 2005 Oct;32(10):3214-24
pubmed: 16279075
Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):734-42
pubmed: 23680034
J Appl Clin Med Phys. 2023 Apr;24(4):e13881
pubmed: 36576418
Med Phys. 2005 May;32(5):1414-23
pubmed: 15984692
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):651-8
pubmed: 20207499

Auteurs

Takayuki Yagihashi (T)

Department of Medical Physics, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.
Graduate School of Human Health Sciences, Tokyo Metropolitan University, 7-2-10 Higashiogu, Arakawa-ku, Tokyo, 116-8551, Japan.

Tatsuya Inoue (T)

Department of Medical Physics, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan. ttinoue@juntendo.ac.jp.
Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. ttinoue@juntendo.ac.jp.

Shintaro Shiba (S)

Department of Radiation Oncology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.

Akihiro Yamano (A)

Department of Medical Physics, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.

Yumiko Minagawa (Y)

Department of Radiation Oncology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.

Motoko Omura (M)

Department of Radiation Oncology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.

Kazumasa Inoue (K)

Graduate School of Human Health Sciences, Tokyo Metropolitan University, 7-2-10 Higashiogu, Arakawa-ku, Tokyo, 116-8551, Japan.

Hironori Nagata (H)

Department of Medical Physics, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of delivery time factor on treatment...
questionsmedicales.fr › Sciences de l'information › Informatique › Informatique médicale › Applications de l'informatique médicale › Prise de décision assistée par ordinateur › Thérapie assistée par ordinateur › Radiothérapie assistée par ordinateur › Radiothérapie conformationnelle › Radiothérapie conformationnelle avec modulation d'intensité › Impact of delivery time factor on treatment...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Impact of delivery time factor on treatment...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Dosimétrie en radiothérapie › Impact of delivery time factor on treatment...
questionsmedicales.fr › Sciences de l'information › Informatique › Informatique médicale › Applications de l'informatique médicale › Prise de décision assistée par ordinateur › Thérapie assistée par ordinateur › Radiothérapie assistée par ordinateur › Planification de radiothérapie assistée par ordinateur › Impact of delivery time factor on treatment...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Impact of delivery time factor on treatment...